Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCKBR | P32239 | 10/20 | 0.52 |
| ▸ | CCKAR | P32238 | 6/20 | 0.48 |
| ▸ | IDO1 | P14902 | 3/20 | 0.46 |
| ▸ | TDO2 | P48775 | 2/20 | 0.46 |
| ▸ | SENP1 | Q9P0U3 | 1/20 | 0.43 |
| ▸ | NAAA | Q02083 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6307970 | 0.92 | CCKBR (0.53) | CCKBRCCKARIDO1TDO2NAAA | |
| SCHEMBL7552319 | 0.89 | CCKBR (0.52) | CCKBRCCKARIDO1TDO2 | |
| SCHEMBL7552311 | 0.89 | CCKBR (0.52) | CCKBRCCKARIDO1TDO2 | |
| SCHEMBL7549407 | 0.89 | CCKBR (0.48) | CCKBRCCKARIDO1TDO2 | |
| SCHEMBL7549412 | 0.89 | CCKBR (0.48) | CCKBRCCKARIDO1TDO2 | |
| SCHEMBL7552285 | 0.89 | CCKBR (0.48) | CCKBRCCKARIDO1TDO2SENP1 | |
| SCHEMBL7552291 | 0.89 | CCKBR (0.48) | CCKBRCCKARIDO1TDO2SENP1 | |
| SCHEMBL7552389 | 0.87 | CCKBR (0.49) | CCKBRCCKARIDO1TDO2 | |
| SCHEMBL7552385 | 0.87 | CCKBR (0.49) | CCKBRCCKARIDO1TDO2 | |
| SCHEMBL6005277 | 0.85 | CCKBR (0.53) | CCKBRCCKARIDO1TDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060217362-A1 | Novel compounds useful for bradykinin B1 receptor antagonism | ELAN PHARMACEUTICALS, INC. | 2006-09-28 | — | — | US | disclosed |
| WO-2006071775-A2 | NOVEL COMPOUNDS USEFUL FOR BRADYKININ B1 RECEPTOR ANTAGONISM | ELAN PHARMACEUTICALS, INC. (US) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217362-A1 | Novel compounds useful for bradykinin B1 receptor antagonism | BDKRB1, BDKRB2, NPBWR1 | CCKBR 37/4885CCKAR 163/4885IDO1 2216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.